Approximately 80% of U.S. HIV/AIDS Patients Live in States Now Providing
Medicaid Coverage for Trofile
SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that New York Medicaid has established coverage and reimbursement for Monogram's Trofile Assay, a diagnostic used to determine patient candidacy for Pfizer's new HIV anti-viral medication Selzentry(TM) (maraviroc).
Initiated in 1989 to ensure early identification and access to quality care for New Yorkers who can't afford medical care, the HIV Primary Care Medicaid Program revised its reimbursement structure in response to advances in HIV treatment and testing technology. With the establishment of coverage by the medicaid program, coverage will also be available from the New York ADAP program so that comprehensive coverage will now be available from all public payers in New York.
"New York remains the epicenter of the HIV/AIDS epidemic in the U.S.," said Dennis deLeon, President of the Latino Commission on AIDS. "The state's coverage and reimbursement of Trofile allows greater access to an advanced treatment option for the most vulnerable of our population living with HIV."
"We are very pleased that New York Medicaid has established coverage for Trofile," said Bill Welch, Monogram Chief Commercial Officer. "Now the medical public assistance programs for the states with the largest numbers of residents living HIV/AIDS -- namely California, Texas, Florida and New York -- recognize the need and provide reimbursement for accurate tropism testing."
Trofile is now a covered benefit among 25 state Medicaid programs,
including California, Florida, Illinois, Maryla
|SOURCE Monogram Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved